Atlas Trials

Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study

Clinical trial NCT05444647 · UNKNOWN

Trial details

NCT number
NCT05444647
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
UNKNOWN
Study type
OBSERVATIONAL
Breast Cancer
Start date
2022-07-01
Primary completion
2024-05-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.